Aethlon Medical, Inc. (AEMD): Price and Financial Metrics

Aethlon Medical, Inc. (AEMD): $3.45

-0.05 (-1.43%)

POWR Rating

Component Grades














  • Sentiment is the dimension where AEMD ranks best; there it ranks ahead of 82.92% of US stocks.
  • AEMD's strongest trending metric is Growth; it's been moving down over the last 47 weeks.
  • AEMD's current lowest rank is in the Stability metric (where it is better than 2.15% of US stocks).

AEMD Stock Summary

  • For AEMD, its debt to operating expenses ratio is greater than that reported by merely 0.46% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, Aethlon Medical Inc's debt growth rate surpasses only 0% of about US stocks.
  • The volatility of Aethlon Medical Inc's share price is greater than that of 97.38% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Aethlon Medical Inc, a group of peers worth examining would be ESTE, HUSA, PED, SOI, and AINC.
  • Visit AEMD's SEC page to see the company's official filings. To visit the company's web site, go to

AEMD Valuation Summary

  • In comparison to the median Healthcare stock, AEMD's price/sales ratio is 537% higher, now standing at 72.3.
  • Over the past 75 months, AEMD's price/earnings ratio has gone up 3.3.
  • AEMD's EV/EBIT ratio has moved up 6.9 over the prior 75 months.

Below are key valuation metrics over time for AEMD.

Stock Date P/S P/B P/E EV/EBIT
AEMD 2021-08-31 72.3 2.3 -6.7 -3.7
AEMD 2021-08-30 70.7 2.2 -6.5 -3.6
AEMD 2021-08-27 77.4 2.5 -7.1 -4.2
AEMD 2021-08-26 70.4 2.2 -6.5 -3.6
AEMD 2021-08-25 70.0 2.2 -6.5 -3.5
AEMD 2021-08-24 66.9 2.1 -6.2 -3.2

AEMD Growth Metrics

  • Its 3 year net income to common stockholders growth rate is now at -27.14%.
  • The 4 year cash and equivalents growth rate now stands at 352.83%.
  • Its 4 year price growth rate is now at -97.34%.
AEMD's revenue has moved up $140,883 over the prior 15 months.

The table below shows AEMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.79107 -7.734795 -8.573729
2021-03-31 0.659104 -6.76494 -7.886709
2020-12-31 0.8316 -6.146664 -7.406645
2020-09-30 0.620187 -5.205643 -5.783334
2020-06-30 0.620187 -5.051896 -5.717807
2020-03-31 0.650187 -5.197608 -6.373948

AEMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AEMD has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
  • AEMD's asset turnover comes in at 0.049 -- ranking 72nd of 75 Measuring and Control Equipment stocks.
  • RLBY, TKOI, and IIVI are the stocks whose asset turnover ratios are most correlated with AEMD.

The table below shows AEMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.049 1 11.337
2021-03-31 0.048 1 10.363
2020-12-31 0.061 1 11.087
2020-09-30 0.053 1 11.287
2020-06-30 0.076 1 13.238
2020-03-31 0.135 1 15.993

AEMD Price Target

For more insight on analysts targets of AEMD, see our AEMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.33 Average Broker Recommendation 1.5 (Moderate Buy)

AEMD Stock Price Chart Interactive Chart >

Price chart for AEMD

AEMD Price/Volume Stats

Current price $3.45 52-week high $12.49
Prev. close $3.50 52-week low $1.29
Day low $3.43 Volume 147,600
Day high $3.58 Avg. volume 2,383,197
50-day MA $4.18 Dividend yield N/A
200-day MA $3.01 Market Cap 53.08M

Aethlon Medical, Inc. (AEMD) Company Bio

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.

AEMD Latest News Stream

Event/Time News Detail
Loading, please wait...

AEMD Latest Social Stream

Loading social stream, please wait...

View Full AEMD Social Stream

Latest AEMD News From Around the Web

Below are the latest news stories about Aethlon Medical Inc that investors may wish to consider to help them evaluate AEMD as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | September 9, 2021

Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference. The conference is being held virtually from September 13-15, 2021.

Yahoo | September 7, 2021

10 Penny Stocks Redditors are Buying in August

In this article, we discuss the 10 penny stocks Redditors are buying in August. If you want to skip our detailed analysis of these stocks, go directly to the 5 Penny Stocks Redditors are Buying in August. Retail investors, who use internet platforms like Reddit for stock research purposes, now control close to one-fifth of […]

Yahoo | August 12, 2021

AEMD: Strong Cash Position to Advance the Hemopurifier; Clinical Trials Move Forward

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT 1Q FY 2022 Results Aethlon Medical (NASDAQ:AEMD) announced results for 1Q FY 2022 (fiscal year ends March) and provided a business update. AEMD generated total revenue of about $132,000. Roughly $115,000 was from government contracts related to AEMD’s phase 2 melanoma cancer contract. In addition, the company recorded revenue of about

Yahoo | August 11, 2021

Aethlon Medical Announces First Quarter Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its first quarter ended June 30, 2021 and provided an update on recent developments.

Yahoo | August 9, 2021

Read More 'AEMD' Stories Here

AEMD Price Returns

1-mo 0.58%
3-mo -37.27%
6-mo 80.63%
1-year 141.26%
3-year -80.51%
5-year -95.23%
YTD 39.68%
2020 156.49%
2019 -96.13%
2018 46.90%
2017 -73.10%
2016 -38.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9054 seconds.